Search Results 1421-1430 of 20485 for hepatitis

1. A Study To Confirm the Effectiveness and Safety of Terlipressin in Adults with Hepatorenal Syndrome Type 1 - Mayo Clinic

   ... hepatitis, or toxins (e.g., Amanita toxin with mushroom poisoning carbon tetrachloride), with the exception of acute alcoholic hepatitis. Proteinuria ...

2. Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

   - Positive test results for hepatitis B surface antigen (HBsAg) or hepatitis C (HCV). - History of infection with human immunodeficiency virus (HIV) unless ...

3. Infectious Diseases - 2013 Archives

   Talking about Hepatitis C, A Mayo Clinic Twitter Chat, Monday, Oct. 7. Dennis Douda. October 4, 2013. First · 1 · 2 · 3 · 4 · Next · Last. Explore more topics.

4. Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer - Mayo Clinic

   Active hepatitis B or hepatitis C infection. Known history of Gilbert's syndrome or is known to have any of the following genotypes: UGT1A1*6/*6, UGT1A1*28 ...

5. Surgery - Doctors - Mayo Clinic

   Hepatitis C, Hepatitis B, Hepatocellular carcinoma, Nonalcoholic fatty liver disease, Cirrhosis, Alcoholic hepatitis, H...epatic encephalopathy, Portal ...

6. Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other Myelodysplastic /Myeloproliferative Neoplasias, and Acute Myeloid Leukemia - Mayo Clinic

   Known infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B or hepatitis C. Concomitant disease or condition that could ...

7. Study of INCB053914 in Subjects With Advanced Malignancies - Mayo Clinic

   Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Active and uncontrolled infectious disease requiring systemic antibiotic ...

8. Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

   ... Hepatitis B or Hepatitis C; Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed four (4) weeks prior to first dose ...

9. Nausea and vomiting - Mayo Clinic

   Hepatitis C: How common is sexual transmission? Hepatitis C: What happens in end-stage liver disease? ... How do COVID-19 antibody tests differ from diagnostic ...

10. A Study to Evaluate the Safety, PK/​PD of (OriCAR-017) in Subjects With RR/​MM - RIGEL Study - Mayo Clinic

    Participation eligibility · Pregnant or breastfeeding. · Seropositive for history of human immunodeficiency virus Active Hepatitis B infection and or Hepatitis C ...